|
Guidance: Single Trial May Be Enough for ABOM Drugs
Sponsors of treatments for acute bacterial otitis media (ABOM), an inflammation of the middle ear, may be able to use a single clinical trial to support an application under some circumstances, according to a final FDA guidance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives